Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 4
2013 4
2014 1
2015 5
2016 1
2017 7
2018 2
2019 1
2020 3
2021 3
2022 6
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH Research Group. Sablerolles RSG, et al. Among authors: postma df. N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045226 Free PMC article. Clinical Trial.
Antibiotic treatment strategies for community-acquired pneumonia in adults.
Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM, Oosterheert JJ, Bonten MJ; CAP-START Study Group. Postma DF, et al. N Engl J Med. 2015 Apr 2;372(14):1312-23. doi: 10.1056/NEJMoa1406330. N Engl J Med. 2015. PMID: 25830421 Free article. Clinical Trial.
Durability of immune responses after boosting in Ad26.COV2.S-primed healthcare workers.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Schmitz KS, Geers D, Bogers S, van Haren E, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Akkerman R, Beukema M, Lafeber M, van Baarle D, de Vries RD, van der Kuy PHM, GeurtsvanKessel CH. Sablerolles RSG, et al. Among authors: postma df. Clin Infect Dis. 2022 Jun 20:ciac495. doi: 10.1093/cid/ciac495. Online ahead of print. Clin Infect Dis. 2022. PMID: 35723273 Free PMC article.
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol.
Tan NH, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, Geers D, Zaeck LM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, van Baarle D, Lafeber M, GeurtsvanKessel CH, de Vries RD, van der Kuy PM. Tan NH, et al. Among authors: postma df. Front Immunol. 2022 Nov 29;13:1067749. doi: 10.3389/fimmu.2022.1067749. eCollection 2022. Front Immunol. 2022. PMID: 36524126 Free PMC article.
Antibiotics for Community-Acquired Pneumonia in Adults.
van Werkhoven CH, Postma DF, Bonten MJ. van Werkhoven CH, et al. Among authors: postma df. N Engl J Med. 2015 Aug 13;373(7):684-6. doi: 10.1056/NEJMc1506892. N Engl J Med. 2015. PMID: 26267636 No abstract available.
Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol.
Sablerolles RSG, Goorhuis A, GeurtsvanKessel CH, de Vries RD, Huckriede ALW, Koopmans MPG, Lafeber M, Postma DF, van Baarle D, Visser LG, Dalm VASH, Kootstra NA, Rietdijk WJR, van der Kuy PHM. Sablerolles RSG, et al. Among authors: postma df. Front Immunol. 2021 Sep 24;12:753319. doi: 10.3389/fimmu.2021.753319. eCollection 2021. Front Immunol. 2021. PMID: 34691071 Free PMC article. No abstract available.
34 results